

Optimizing Xevo G2-XS QToF Quadrupole Settings to Increase Sensitivity and Dynamic Range for the Analysis of Trastuzumab

Marian Twohig, Yun Wang Alelyunas, Caitlin Dunning, Mark D. Wrona

Waters Corporation

Abstract

This application brief demonstrates to how to enhance selectivity by optimizing quadrupole settings on a quadrupole time-of-flight high resolution mass spectrometer (Q-ToF HRMS) for sensitive quantitation of surrogate peptides in complex matrices.

Benefits

The development of complex biotherapeutic modalities has led to a need for sensitive and selective quantitative LC-MS techniques that complement and serve as an alternative to ligand binding assays in discovery.

Introduction

The development of complex biotherapeutic modalities has led to a need for sensitive and selective quantitative

LC-MS techniques that complement and serve as an alternative to ligand binding assays in discovery.^{1,2} High resolution mass spectrometry (HRMS) has certain advantages over tandem quad mass spectrometry, including high mass resolving power for additional selectivity when faced with a challenging sample and a wider mass range for intact quantification of larger proteins. A single platform for both characterization, as well as targeted modes for quantitation is attractive, providing increased laboratory flexibility.

The surrogate peptide approach is commonly used for protein bioanalysis. Direct digestion of plasma/tissue often results in significant endogenous interference (at both the peptide and fragment level) which can impact both the selectivity and sensitivity of quantitative LC-MS assays for antibody and other protein based drugs. Sample preparation clean-up strategies including immunoaffinity and solid phase extraction are often used to reduce sample complexity and aid in improving selectivity and sensitivity. Optimizing the quadrupole mass selection window on a Q-ToF HRMS can be used to balance the ability to remove matrix interference through selectivity while maximizing sensitivity of a bioanalytical assay.

Results and Discussion

In this study, quantification of the therapeutic monoclonal antibody, digested trastuzumab, prepared in rat plasma, is demonstrated. Peptide quantitation was performed using HRMS with a Xevo G2-XS QToF which was operated in sensitivity (ESI+) mode and MassLynx Software v4.1. Time-of-flight multiple reaction monitoring (ToF-MRM) was used as the mode of data acquisition.³ The quadrupole mass selection window was varied from 1 Da to 4 Da (LM settings were tuned using leucine enkephalin from 4.7 to 15). HM settings were not adjusted. Data was collected from 200 m/z to 1500 m/z and the system calibrated using sodium iodide solution clusters.

Two unique tryptic peptides of trastuzumab, FTISADTSK and DTYIHWVR analyzed in plasma, were used to demonstrate the benefit of optimizing the quadrupole mass selection window. The m/z of the peptides, their fragments, and corresponding charge states are listed in Table 1.

Peptide sequence	Precursor charge state	Precursor (m/z)	Product ion (m/z)	Product ion charge state	Product ion	Cone voltage	CE
FTISADTSK	[M+2H] ²⁺	485.2480	721.3727	1+	y7	40	16
DTYIHWVR	[M+2H] ²⁺	545.2774	597.3256	1+	y4	40	23

Table 1. Peptide sequence, m/z of peptides, m/z fragments, and corresponding charge states for trastuzumab tryptic peptides used for quantitation.

Chromatographic separation was achieved using an ACQUITY UPLC H-Class System with an ACQUITY UPLC Peptide BEH C₁₈ Column (P/N 186003687), and a gradient (5–50% B) over eight minutes with 0.1% formic acid in both water and acetonitrile (flow rate 0.3 mL/min). Briefly, trastuzumab was purified from rat plasma (50 µL) using affinity capture magnetic Protein A beads.⁴ The post affinity purified plasma was then digested and peptide-level purification was completed using the ProteinWorks eXpress Digest Kit (P/N 176003689) and a ProteinWorks µElution SPE Clean-up Kit (P/N 186008304). A 10 µL aliquot of the resulting 90 µL SPE eluate was injected for each LC-MS analysis.³ The data was processed using TargetLynx Application Manager with a mass extraction window of 50 mDa.

During the digestion process, hundreds of peptides are formed, interference from these peptides is to be expected. When matrix interference occurs close to the target peptide fragment, it can result in poor selectivity and sensitivity. The quadrupole mass selection window can be optimized to either increase transmission of the precursor in relatively clean samples or reduce the transmission of closely eluting peptides of similar mass that generate fragments with mass-to-charge ratios in close proximity or isobaric to the target peptide fragments as is shown in Figure 1. In this example, optimizing the quadrupole mass selection window improved sensitivity and S/N at the low end of the curve by 4 to 8 fold. Although counts were reduced, the decrease in matrix interference significantly improved the results.




Figure 1. Tof-MRM chromatograms resulting from the separation of DTYIHWVR (XIC m/z 597.3256 using a 50 mDa mass extraction window, 0.050 $\mu\text{g/mL}$ in rat plasma). The quadrupole mass selection window was varied between 1–4 Da. The expanded baseline for the 4 Da quadrupole mass selection window is shown inset.




Figure 2. ToF MRM XIC chromatograms for the trastuzumab tryptic peptide fragments: FTISADTSK (m/z 721.3727) and DTYIHWVR (m/z 597.3256) with a mass extraction window of 50 mDa analyzed in rat plasma. The quadrupole mass selection window is shown at 1 Da and 4 Da.

When the quadrupole mass selection window is set to transmit a 4 Da window, matrix interference, which produces an isobaric fragment, elutes in close proximity to the target peptide (Figure 1). The presence of this prominent matrix interference can hinder automatic peak integration across the calibration range. The 3 Da window readily removes the largest interfering peak and might be suitable for some assays. In this example, we preferred 1 Da to maximize the robustness of the assay and remove as much background interference as possible. Setting up the quadrupole to transmit a 1 Da window has the effect of significantly decreasing the intensity of the interference and increasing selectivity and sensitivity (Figure 1). The absolute intensity of the target peptide fragments decreases, however, the signal-to-noise ratio (S/N) at the LLOQ for DTYIHWVR (0.05 µg/mL, 10 µL injection) and FTISADTSK (0.025 µg/mL, 10 µL injection) in this matrix improves. Table 2 shows the effect of narrowing the quadrupole mass selection window and its relationship to peak area, peak height and signal-to-noise (S/N). In this example, changing the quadrupole mass selection window also resulted in a clear increase in dynamic range for both peptides. The calibration plots also revealed that each peptide gained half an order of magnitude using this approach (Figure 3).

DTYIHWVR - 0.050 µg/mL				FTISADTSK - 0.025 µg/mL		
Quadrupole mass filter setting	S/N	Peak area	Peak height	S/N	Peak area	Peak height
4 Da	1.57	13	440	2.56	46	1095
3 Da	6.95	14	417	7.49	41	845
1 Da	16.1	8	246	10	25	538

Table 2. Data shows the effect of changing the quadrupole settings on the peak attributes for the LLOQ of the DTYIHWVR and FTISADTSK peptides.




Figure 3. Calibration curves showing plot response versus concentration for DTYIHWVR and FTISADTSK with the quadrupole selection window set at 1 and 4 Da.

The presence of closely eluting matrix peaks can often complicate automatic peak integration of the target analyte. In this example, due to the removal of the interfering peaks, the data processing was simplified leading to more efficient data analysis and reporting.

Conclusion

Isobaric (or close mass to charge) interferences can occur during the analysis of peptides in complex matrices such as plasma/serum and should be investigated during method development. This can impact both the selectivity and sensitivity of quantitative LC-MS assays for antibody and other protein based drugs. Sample preparation, and MS optimization including an optimal quadrupole mass selection window should be used to reduce potential matrix interferences that are close in mass and chromatographic retention time to the peptide and fragment of interest to maximize sensitivity and assay robustness.

References

1. Fumin Li, Douglas Fast, Steve Michael. *Absolute quantitation of protein therapeutics in biological matrices by enzymatic digestion and LC-MS*. (2011) Bioanalysis 3(21), 2459–2480.
2. Timothy V Olah. *Quantitation of therapeutic proteins following direct trypsin digestion of dried blood spot samples and detection by LC-MS-based bioanalytical methods in drug discovery*. (2012) 4(1), 29–40.
3. Mary Lame, Caitlin Dunning, Yun Alelyunas, Mark Wrona. *Comparison of tandem and high resolution mass spectrometry for the quantification of the monoclonal antibody, trastuzumab in plasma*. Waters Corporation. 720006207EN. 2018.
4. <https://www.promega.com/products/biologics/antibody-characterization/magne-protein-g-beads-magne-protein-a-beads/?catNum=G8782>.

Featured Products

ACQUITY UPLC H-Class PLUS System <<https://www.waters.com/10138533>>

Xevo G2-XS QToF Quadrupole Time-of-Flight Mass Spectrometry <<https://www.waters.com/134798222>>

TargetLynx <<https://www.waters.com/513791>>

MassLynx MS Software <<https://www.waters.com/513662>>

720006444, December 2018

©2019 Waters Corporation. All Rights Reserved.